Previous 10 | Next 10 |
2023-06-06 09:49:10 ET Following a ~31% decline in the previous session, the shares of PDS Biotechnology ( NASDAQ: PDSB ) rose ~9% in the pre-market Tuesday as Cantor Fitzgerald and H.C. Wainwright defended the stock arguing that the selloff was overdone. H.C. Wainwright analyst...
2023-06-06 08:37:27 ET Brera Holdings ( BREA ) +104% Acquires Strategic Stake in Manchester United PLC. Hoth Therapeutics ( HOTH ) +24% Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease. GitLab ( GTLB ) +27% Q1 earnings ca...
FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will be hosting a conference cal...
2023-06-05 13:06:50 ET Gainers: Forza X1 ( FRZA ) +164% . Sono Group ( SEV ) +123% . Chijet Motor Company ( CJET ) +62% . CIRCOR International ( CIR ) +51% . Timber Pharmaceuticals ( TMBR ) +44% . TOP Financial Group ( TOP ...
2023-05-27 03:40:53 ET Summary PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival rate for ICI naive patients, nearly doubling typical rates from similar treatments. Despite higher...
2023-05-26 10:05:44 ET Gainers: Elevation Oncology ( ELEV ) +58% . Arcus Biosciences ( RCUS ) +26% . Healthcare Triangle ( HCTI ) +17% . PDS Biotechnology ( PDSB ) +16% . NEXGEL ( NXGL ) +12% . Losers: Tilray Brands (...
2023-05-26 06:53:18 ET PDS Biotechnology ( NASDAQ: PDSB ) added ~20% pre-market Friday after announcing interim Phase 2 data for its lead candidate PDS0101 in combination with Merck's ( NYSE: MRK ) anti-PD-1 therapy, Keytruda in certain patients with human papillomavirus...
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1% A disease control rate (disease stabilization or tumor shrinkage) of 70.6% Median o...
2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced the completion of enrollment in the immune che...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NASDAQ Market:
PDS Biotechnology Corporation Website:
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectiou...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...